Physician profile
Mark R Brown
NPI 1982604880
$1,645.41
in general payments reported to CMS, 2019-2025
15 companies · $159 in 2025
The $159 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $36.26 · 2021: $337 · 2022: $392 · 2023: $387 · 2024: $190 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $776.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $270.31 | 2021-2024 | Ubrelvy, Qulipta |
| Abbott Laboratories | $124.09 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $104.85 | 2019-2025 | |
| Novo Nordisk INC | $73.34 | 2022-2025 | Ozempic, Rybelsus |
| Amgen INC. | $67.52 | 2021-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $42.73 | 2022-2023 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company Ltd. | $38.40 | 2022 | |
| Exact Sciences Corporation | $31.65 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $28.49 | 2021-2022 | |
| Lilly USA, LLC | $23.27 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.14 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.75 | 2022 | |
| Dexcom, INC. | $14.50 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.